+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2 kd/kd Mice



Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2 kd/kd Mice



Biological and Pharmaceutical Bulletin 40(1): 34-42



Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid that possesses many pharmacological effects, including increasing bile flow, changing the hydrophobicity of the bile acid pool, and modulation of the immune response. UDCA has been approved for treating cholestatic liver disease, such as primary biliary cholangitis. However, several unanticipated severe side effects of UDCA are observed in cholestatic patients, and its pharmacological benefits remain controversial. We reported that ezrin-knockdown (Vil2kd/kd) mice exhibited severe hepatic injury because of a functional disorder in bile duct fluidity and alkalinity regulation, resembling human intrahepatic cholestatic disease. Here we used Vil2kd/kd mice as a cholestatic model to investigate the pharmacological effects of UDCA. We investigated the effects of oral and parenteral administration of UDCA on Vil2kd/kd mice. In Vil2kd/kd mice, fed a 0.5% (w/w) UDCA diet for 3 weeks, hepatic injury was exacerbated, although oral administration of a lower dose of UDCA slightly improved hepatic function in Vil2kd/kd mice. On the other hand, intraperitoneal administration of UDCA (50 mg/kg/d) ameliorated hepatic function and markedly reduced periductal fibrosis and cholangiocyte proliferation in Vil2kd/kd mice although biliary pH and HCO3- concentration were not improved. The expression levels of inflammatory and profibrotic genes were also significantly decreased in these mice. Furthermore, UDCA prevented cholangiocytes from hydrophobic bile acid-induced cytotoxicity independent of extracellular pH in in vitro experiments. These results suggest that an appropriate dosage of UDCA can ameliorate the intrahepatic cholestasis in Vil2kd/kd mice without changing the biliary bicarbonate secretion.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 060446977

Download citation: RISBibTeXText

PMID: 28049946

DOI: 10.1248/bpb.b16-00529


Related references

Mechanism of ursodeoxycholic acid- and canrenoate-induced biliary bicarbonate secretion and the effect on glucose- and amino acid-induced cholestasis. Scandinavian Journal of Gastroenterology 26(5): 513-522, 1991

Ursodeoxycholic acid ameliorates parameters of cholestasis, but does not prevent collagen accumulation in rat secondary biliary liver fibrosis. Journal of Hepatology 26(SUPPL 1): 184, 1997

Effect of ursodeoxycholic acid administration on the biliary mass of unconjugated bile acids in chronic intrahepatic cholestasis. Hepatology 18(4 PART 2): 297A, 1993

Effect of cholestasis on biliary secretion of ursodeoxycholic acid sulfate in man. Gastroenterology 116(4 PART 2): A1268, 1999

Ursodeoxycholic acid udca decreases serum cholesterol levels ameliorates symptoms and improves biochemical parameters in pediatric patients with chronic intrahepatic cholestasis. Gastroenterology 98(5 PART 2): A566, 1990

Ursodeoxycholic acid induced biliary bicarbonate secretion is inhibited by heavy water. Journal of Hepatology 11(SUPPL 2): S30, 1990

Effects of Na+ replacement and amiloride on ursodeoxycholic acid-stimulated choleresis and biliary bicarbonate secretion. American Journal of Physiology 252(2 Pt 1): G163-G169, 1987

Different effects of ursodeoxycholic acid on intrahepatic cholestasis in acute and recovery stages induced by alpha-naphthylisothiocyanate in mice. Toxicology and Applied Pharmacology 342: 69-78, 2018

Different effects of ursodeoxycholic acid on intrahepatic cholestasis in acute and recovery stages induced by alpha-naphthylisothiocyanate in mice. Toxicology and Applied Pharmacology 342: 69-78, 2018

Effects of sodium replacement and amiloride on ursodeoxycholic acid stimulated choleresis and biliary bicarbonate secretion. American Journal of Physiology 252(2 PART 1): G163-G169, 1987

Ursodeoxycholic acid treatment shortens the course of cholestasis in two patients with benign recurrent intrahepatic cholestasis. Gastroenterologia Y Hepatologia 26(7): 421-423, 2003

Failure of ursodeoxycholic acid udca to prevent the occurrence of cholestasis in benign recurrent intrahepatic cholestasis bric. Gastroenterology 98(5 PART 2): A578, 1990

Ursodeoxycholic acid choleresis relationship to biliary bicarbonate secretion and further evidence of a role for sodium proton exchange. Hepatology 5(5): 1011, 1985

Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. Journal of Hepatology 23(3): 283-289, 1995

Effect of maternal cholestasis and treatment with ursodeoxycholic acid on the expression of genes involved in the secretion of biliary lipids by the neonatal rat liver. Life Sciences 79(10): 1014-1019, 2006